STAGE III BREAST CANCER

This early-phase trial tests a DNA vaccine called STEMVAC in 42 people with advanced HER2-negative breast cancer. The vaccine is designed to help the immune system recognize and attack cancer stem cells, which are often resistant to standard treatments. The main goals are to chec…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that still remains after initial chemotherapy and surgery. About 415 participants with stage II or III bre…

This study tested whether adding trastuzumab to standard chemotherapy before surgery helps shrink breast tumors more effectively. About 92 women with early-stage breast cancer (some HER2-positive, some HER2-negative) took part. The goal was to see if the combination reduces the a…

This study tests whether combining the immunotherapy drug avelumab with other medications can help people with advanced triple-negative breast cancer. About 145 adults with stage IV or inoperable breast cancer will receive one of several drug combinations. The goal is to see if t…

This study looks at whether aerobic exercise can lower ctDNA levels in the blood, which may help prevent cancer from returning. About 33 people who have been treated for high-risk breast, prostate, or colorectal cancer will try different amounts of weekly exercise to find the saf…

This study tests whether a newer drug, margetuximab, works better than the standard trastuzumab when combined with chemotherapy and pertuzumab before surgery for stage II-III HER2-positive breast cancer. About 174 participants will receive one of the two combinations. The main go…

This study tests two targeted drugs, T-DM1 and pertuzumab, given before surgery to people with early-stage HER2-positive breast cancer. The goal is to see if this combination can completely eliminate cancer cells in the breast, potentially reducing the need for more aggressive tr…